Nicotinamide mononucleotide (NMN) is a key precursor metabolite of NAD+, a large number of studies have shown that NMN has a significant therapeutic effect on age-related diseases. However, a systematic assessment of NMN subacute toxicity remains to be determined.
Recently, researchers from the Biochemical Interdisciplinary Research Center of the Shanghai Institute of Organic Chemistry published an article on Frontiers in Pharmacology, taking mice and Beagle dogs as research objects, and systematically expounding the subacute toxicity of NMN. In the study, both animals were gavaged with a saturated aqueous solution of NMN (67mg/ml) at the maximum dose (20ml/kg) for 7 or 14 days, once or twice a day, as shown in Figure 1.
The findings showed that in mice, NMN administered once daily for seven days was well tolerated with minimal toxicity. At higher doses, a slight increase in alanine aminotransferase levels was observed, while other biomarkers remained unchanged, as shown in Figure 2.
Similarly, the use of NMN in beagle dogs resulted in only mild increases in creatinine and uric acid, while other biomarkers did not change significantly, as shown in Figure 3.
Interestingly, blood lipid measurements including total cholesterol, triglycerides, and LDL cholesterol were significantly reduced in mice receiving high NMN doses, suggesting that lipid metabolic processes were significantly upregulated, as shown in Figure 4, which It will bring new opportunities for the treatment of diseases related to abnormal lipid metabolism.
Although this research on NMN is short-term, it is enough to provide a solid foundation for the safety of NMN.
EFFEPHARM is committed to providing high-quality health raw materials and sharing cutting-edge health information.